CND261 / Candid Therapeutics - LARVOL DELTA

An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis (clinicaltrials.gov) - P1 | N=47 | Recruiting | Sponsor: Candid Therapeutics

New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation (Businesswire) - "First patients dosed with cizutamig and CND261: Patients with refractory rheumatoid arthritis and systemic sclerosis have been dosed at therapeutically active doses."

Trial status • Rheumatoid Arthritis • Systemic Sclerosis